Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy

The Pharmacogenomics Journal volume 18, pages 713–720 (2018)Cite this article

Subjects

Abstract

Clopidogrel resistance is prevalent in chronic kidney disease (CKD) patients. Genetic polymorphism is considered to be the most important factor that influences clopidogrel resistance. Limited data exist as to the role of pharmacogenetics in prognosis of stroke patients with impaired renal function on clopidogrel. We sought to explore whether decreased kidney function alters the association between CYP2C19 genetic variants and clinical outcome in patients with minor stroke or transient ischemic attack (TIA) receiving clopidogrel therapy. A total of 1476 participants on clopidogrel-aspirin treatment with genotyping results in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial were categorized by quintiles of renal function estimated by estimated glomerular filtration rate (eGFR), and were stratified according to the possession of CYP2C19 loss-of-function (LOF) alleles: carriers and non-carriers. Patients were followed up and clinical outcomes were evaluated. The primary efficacy outcome was new stroke. The secondary efficacy outcome was combined vascular events (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death). The safety outcome was bleeding event. CYP2C19 LOF carriers had higher odds of new stroke than non-carriers (10.4% versus 2.4 %, hazard ratio [HR], 5.30; 95% CI, 1.51–18.3, P = 0.009) in the lowest quintile of renal function group with eGFR < 75 ml/min/1.73 m2 but not in the other four higher quintiles. Similar results were observed for the ischemic stroke and combined vascular events. There was no significant difference in the individual outcomes of bleeding in carriers compared with non-carriers in any renal function group. Among patients with minor stroke or TIA taking clopidogrel-aspirin treatment, CYP2C19 LOF carrier state was associated with higher risk of new stroke in those with eGFR < 75 ml/min/1.73 m2. This observation supports that the evaluation of CYP2C19 LOF carrier state may be useful for identification of the patients with kidney impairment with greater likelihood of having worse outcomes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Chen CY, Lee KT, Lee CT, Lai WT, Huang YB. Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. Int J Stroke. 2014;9:580–90.

    Article  Google Scholar 

  2. Mostofsky E, Wellenius GA, Noheria A, Levitan EB, Burger MR, Schlaug G, et al. Renal function predicts survival in patients with acute ischemic stroke. Cerebrovasc Dis. 2009;28:88–94.

    Article  Google Scholar 

  3. Htun P, Fateh-Moghadam S, Bischofs C, Banya W, Muller K, Bigalke B, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol. 2011;22:627–33.

    Article  CAS  Google Scholar 

  4. Steinhubl SR. Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines. Circulation. 2010;121:481–3.

    Article  Google Scholar 

  5. Baber U, Mehran R, Kirtane AJ, Gurbel PA, Christodoulidis G, Maehara A, et al. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ Cardiovasc Interv. 2015;8:e001683.

    PubMed  Google Scholar 

  6. Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol. 2001;12:326–32.

    CAS  PubMed  Google Scholar 

  7. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4:1065–74.

    Article  CAS  Google Scholar 

  8. Ladda MA, Goralski KB. The effects of CKD on cytochrome P450-mediated drug metabolism. Adv Chronic Kidney Dis. 2016;23:67–75.

    Article  Google Scholar 

  9. Barnes KJ, Rowland A, Polasek TM, Miners JO. Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol. 2014;70:1097–106.

    Article  CAS  Google Scholar 

  10. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369:11–19.

    Article  CAS  Google Scholar 

  11. Wang Y, Pan Y, Zhao X, Li H, Wang D, Johnston SC, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial: one-year outcomes. Circulation. 2015;132:40–46.

    Article  CAS  Google Scholar 

  12. Wang Y, Johnston SC. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J. 2010;160:380–6 e381.

    Article  CAS  Google Scholar 

  13. Teo BW, Xu H, Wang D, Li J, Sinha AK, Shuter B, et al. GFR estimating equations in a multiethnic Asian population. Am J Kidney Dis. 2011;58:56–63.

    Article  Google Scholar 

  14. Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA. 2016;316:70–78.

    Article  CAS  Google Scholar 

  15. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–82.

    Article  Google Scholar 

  16. Zhou Y, Pan Y, Wu Y, Zhao X, Li H, Wang D, et al. Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack: CHANCE substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). Stroke. 2016;47:2791–6.

    Article  CAS  Google Scholar 

  17. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505–16.

    Article  CAS  Google Scholar 

  18. Morel O, El Ghannudi S, Jesel L, Radulescu B, Meyer N, Wiesel ML, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011;57:399–408.

    Article  CAS  Google Scholar 

  19. Gremmel T, Muller M, Steiner S, Seidinger D, Koppensteiner R, Kopp CW, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant. 2013;28:2116–22.

    Article  CAS  Google Scholar 

  20. Viviani Anselmi C, Briguori C, Roncarati R, Papa L, Visconti G, Focaccio A, et al. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv. 2013;6:1166–75.

    Article  Google Scholar 

  21. Tornio A, Flynn R, Morant S, Velten E, Palmer CNA, MacDonald TM, et al. Investigating real-world clopidogrel pharmacogenetics in stroke using a bioresource linked to electronic medical records. Clin Pharmacol Ther. 2017;103:281–6.

    Article  Google Scholar 

  22. Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation. 2017;135:21–33.

    Article  CAS  Google Scholar 

  23. Tabata N, Hokimoto S, Akasaka T, Arima Y, Kaikita K, Kumagae N, et al. Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation. Thromb Res. 2014;134:939–44.

    Article  CAS  Google Scholar 

  24. Yang J, Zhao HD, Tan J, Ding YL, Gu ZQ, Zou JJ. CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients. Pharmazie. 2013;68:183–6.

    CAS  PubMed  Google Scholar 

  25. Jia DM, Chen ZB, Zhang MJ, Yang WJ, Jin JL, Xia YQ, et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke. 2013;44:1717–9.

    Article  CAS  Google Scholar 

  26. Linthorst GE, Folman CC, van Olden RW, von dem Borne AE. Plasma thrombopoietin levels in patients with chronic renal failure. Hematol J. 2002;3:38–42.

    Article  CAS  Google Scholar 

  27. Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 2009;104:1292–5.

    Article  CAS  Google Scholar 

  28. Pattaro C, Teumer A, Gorski M, Chu AY, Li M, Mijatovic V, et al. Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nat Commun. 2016;7:10023.

    Article  CAS  Google Scholar 

  29. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–62.

    Article  CAS  Google Scholar 

Download references

Funding

This study is supported by grants from the Ministry of Science and Technology of the People’s Republic of China (2013BAI09B03, 2013BAI09B14, 2015BAI12B04, 2015BAI12B02), a grant from the Beijing Biobank of Cerebral Vascular Disease (D131100005313003), a grant from Beijing Institute for Brain Disorders (1152130306), a grant from the National Natural Science Foundation of China (No. 81322019), grants from Beijing Municipal Science and Technology Commission (No. D131100002313002, D151100002015001, D151100002015002, D151100002015003, Z15110200390000, Z151100003915117), a grant from Beijing high-level talents in health-care system (2014-3-021), grants from Beijing Municipal Commission of Health and Family Planning (No. 2016-1-2041, SML20150502).

Author information

Author notes

  1. These authors contributed equally: Yu Wu, Yilun Zhou, and Yuesong Pan.

Authors and Affiliations

  1. Department of Nephrology, Beijing Tiantan hospital, Capital Medical University, Beijing, China

    Yu Wu & Yilun Zhou

  2. Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing, China

    Yuesong Pan

  3. Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China

    Yuesong Pan

  4. Department of Neurology, Beijing Tiantan hospital, Capital Medical University, Beijing, China

    Xingquan Zhao, Liping Liu, Chunxue Wang, Hao Li, Xia Meng, Yilong Wang & Yongjun Wang

  5. INI Stroke Network, OSF Healthcare System, University of Illinois College of Medicine, Peoria, USA

    David Wang

  6. Dell Medical School, University of Texas at Austin, Austin, USA

    S. Claiborne Johnston

Authors
  1. Yu Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yilun Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuesong Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xingquan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Liping Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chunxue Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Claiborne Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xia Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yilong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yongjun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the CHANCE Investigators

Corresponding authors

Correspondence to Yilong Wang or Yongjun Wang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, Y., Zhou, Y., Pan, Y. et al. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics J 18, 713–720 (2018). https://doi.org/10.1038/s41397-018-0018-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41397-018-0018-4

This article is cited by

Search

Advanced search

Quick links